AtriCure, Inc.

NasdaqGM:ATRC

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

Location

United States

Market Cap

USD 1.63 B

Share Price

USD 32.28

Avg Daily Volume

628,522

Change (1 day)

-1.82%

Change (1 year)

38.60%

Change (YTD)

5.63%

AtriCure, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 74.60%

AtriCure, Inc. Gross Profit Margin is 74.60% for the Trailing 12 Months (TTM) ending March 31, 2025, a -0.41% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

AtriCure, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 74.90%, a 0.65% change year over year.
AtriCure, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 74.42%, a -0.63% change year over year.
AtriCure, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 74.89%, a 2.74% change year over year.
AtriCure, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 72.90%, a -0.97% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Gross Profit Margin	EBIT Margin	EBITDA Margin	Net Income Margin

NasdaqGM: ATRC

AtriCure, Inc.

CEO	Mr. Michael H. Carrel
IPO Date	Aug. 5, 2005
Location	United States
Headquarters	7555 Innovation Way
Employees	1,300
Sector	🏥 Health Care
Industries Medical Instruments

Description

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.